US Biodefense Market Outlook 2022
The dangers posed by the weapons of mass destruction have caught the attention of every nation worldwide. These weapons can be characterized by their potential for large-scale destruction and the indiscriminate nature of their effects, notably against civilians. Increasing threat of biological, chemical as well as nuclear terrorism and disease outbreaks; along with growing R&D investments in the field of biotechnology is expected to drive biodefense market growth with a CAGR of 9% during the forecasted period of 2017-2022.
The report “US Biodefense Market Outlook 2022” unfolds the market scenario of the US BioDefense market. The report provides an overview of the Biodefense market with respect to biological defense. It further gives a detailed analysis of its sub-segment, with an in-depth study of the Biodefense market scenario prevalent in the country.
A detailed analysis was carried out in the research to understand the significance of the biodefense market in United States, which revealed that Anthrax is the biggest bioterrorism threat to the country, as it is highly infectious and communicable. The other major threats are Small Pox and Botulism. Further, a meticulous category-wise segmentation has provided the understanding of the biodefense-related demand parameters prevailing in the country.
The latter half of the report provides the status of the current rules and regulations that govern the Biodefense market. It also focuses on the analysis of current drivers, and the challenges of the market. The report further highlights the competitive landscape of the US BioDefense market, describing the business of the major industry players. On the whole, the report provides all the pre-requisite information for clients looking to make a debut in this industry, and facilitates them to formulate schemes while going for an investment/partnership in the US BioDefense industry.
The report “US Biodefense Market Outlook 2022” unfolds the market scenario of the US BioDefense market. The report provides an overview of the Biodefense market with respect to biological defense. It further gives a detailed analysis of its sub-segment, with an in-depth study of the Biodefense market scenario prevalent in the country.
A detailed analysis was carried out in the research to understand the significance of the biodefense market in United States, which revealed that Anthrax is the biggest bioterrorism threat to the country, as it is highly infectious and communicable. The other major threats are Small Pox and Botulism. Further, a meticulous category-wise segmentation has provided the understanding of the biodefense-related demand parameters prevailing in the country.
The latter half of the report provides the status of the current rules and regulations that govern the Biodefense market. It also focuses on the analysis of current drivers, and the challenges of the market. The report further highlights the competitive landscape of the US BioDefense market, describing the business of the major industry players. On the whole, the report provides all the pre-requisite information for clients looking to make a debut in this industry, and facilitates them to formulate schemes while going for an investment/partnership in the US BioDefense industry.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. BIODEFENSE - AN INTRODUCTION
4. GLOBAL BIODEFENSE INDUSTRY
5. BIODEFENSE INDUSTRY MARKET OUTLOOK TO 2022
5.1 Anthrax
5.2 Small Pox
5.3 Botulism
5.4 Radiation
6. INDUSTRY DRIVERS
6.1 Innovative Technology Advancing the BioDefense Industry
6.2 Government Initiatives Contributing to BioDefense Infrastructure
6.3 Research and Development Enhancing Drug Efficiency
7. INDUSTRY ROADBLOCKS
7.1 Biological threat detection: A National Challenge
7.2 Stringent Norms: Barriers to Clinical Testing
8. REGULATORY FRAMEWORK
9. COMPETITIVE LANDSCAPE
9.1 PharmAthene, Inc.
9.1.1 Business Description
9.1.2 Financial Overview
9.2 Emergent BioSolutions
9.2.1 Business Description
9.2.2 Financial Overview
9.2.3 Recent Developments
9.3 Dynavax Technologies Corporation
9.3.1 Business Description
9.3.2 Financial Overview
9.4 SIGA Technologies, Inc.
9.4.1 Business Description
9.4.2 Financial Overview
9.4.3 Recent Developments
9.5 Alnylam Pharmaceuticals, Inc.
9.5.1 Business Description
9.5.2 Financial Overview
9.5.3 Recent Developments
9.6 Cleveland Biolabs, Inc.
9.6.1 Business Description
9.6.2 Financial Overview
2. RESEARCH METHODOLOGY
3. BIODEFENSE - AN INTRODUCTION
4. GLOBAL BIODEFENSE INDUSTRY
5. BIODEFENSE INDUSTRY MARKET OUTLOOK TO 2022
5.1 Anthrax
5.2 Small Pox
5.3 Botulism
5.4 Radiation
6. INDUSTRY DRIVERS
6.1 Innovative Technology Advancing the BioDefense Industry
6.2 Government Initiatives Contributing to BioDefense Infrastructure
6.3 Research and Development Enhancing Drug Efficiency
7. INDUSTRY ROADBLOCKS
7.1 Biological threat detection: A National Challenge
7.2 Stringent Norms: Barriers to Clinical Testing
8. REGULATORY FRAMEWORK
9. COMPETITIVE LANDSCAPE
9.1 PharmAthene, Inc.
9.1.1 Business Description
9.1.2 Financial Overview
9.2 Emergent BioSolutions
9.2.1 Business Description
9.2.2 Financial Overview
9.2.3 Recent Developments
9.3 Dynavax Technologies Corporation
9.3.1 Business Description
9.3.2 Financial Overview
9.4 SIGA Technologies, Inc.
9.4.1 Business Description
9.4.2 Financial Overview
9.4.3 Recent Developments
9.5 Alnylam Pharmaceuticals, Inc.
9.5.1 Business Description
9.5.2 Financial Overview
9.5.3 Recent Developments
9.6 Cleveland Biolabs, Inc.
9.6.1 Business Description
9.6.2 Financial Overview
LIST OF TABLES
Table 3-1: Biological Weapons by Type
Table 6-1: Product Pipeline by Phase, 2016
Table 9-1: PharmAthene, Inc. - Key Financials (Million US$), 2013-2015
Table 9-2: Emergent Biosolutions - Key Financials (Million US$), 2013-2015
Table 9-3: Dynavax Technologies - Key Financials (Million US$), 2013-2015
Table 9-4: Siga Technologies - Key Financials (Million US$), 2013-2015
Table 9-5: Alnylam Pharmaceuticals, Inc. - Key Financials (Million US$), 2013-2015
Table 9-6: Cleveland Biolabs, Inc. - Key Financials (Million US$), 2013-2015
Table 3-1: Biological Weapons by Type
Table 6-1: Product Pipeline by Phase, 2016
Table 9-1: PharmAthene, Inc. - Key Financials (Million US$), 2013-2015
Table 9-2: Emergent Biosolutions - Key Financials (Million US$), 2013-2015
Table 9-3: Dynavax Technologies - Key Financials (Million US$), 2013-2015
Table 9-4: Siga Technologies - Key Financials (Million US$), 2013-2015
Table 9-5: Alnylam Pharmaceuticals, Inc. - Key Financials (Million US$), 2013-2015
Table 9-6: Cleveland Biolabs, Inc. - Key Financials (Million US$), 2013-2015
LIST OF FIGURES
Figure 4-1: Share of US BioDefense Market, 2016
Figure 5-1: BioDefense Market (Billion US$), 2015-2022
Figure 5-2: BioDefense Market by Product (%), 2016
Figure 5-3: Anthrax BioDefense Market (Billion US$), 2015-2022
Figure 5-4: Small Pox BioDefense Market (Billion US$), 2015-2022
Figure 5-5: Botulism BioDefense Market (Billion US$), 2015-2022
Figure 5-6: Radiation/Nuclear BioDefense Market (Billion US$), 2015-2022
Figure 4-1: Share of US BioDefense Market, 2016
Figure 5-1: BioDefense Market (Billion US$), 2015-2022
Figure 5-2: BioDefense Market by Product (%), 2016
Figure 5-3: Anthrax BioDefense Market (Billion US$), 2015-2022
Figure 5-4: Small Pox BioDefense Market (Billion US$), 2015-2022
Figure 5-5: Botulism BioDefense Market (Billion US$), 2015-2022
Figure 5-6: Radiation/Nuclear BioDefense Market (Billion US$), 2015-2022
